Liquid chromatography–tandem mass spectrometry (LC–MS/MS) reveals distinct sphingolipid patterns in anorexia and obesity.
|Articles|April 1, 2005
- LCGC Europe-04-01-2005
- Volume 18
- Issue 4
Emerging Technologies in the MS Arsenal
Author(s)Michael P. Balogh
This month’s column provides an overview of several recently developed technologies that aim to improve the utility and performance of mass spectrometers in a number of applications.
Advertisement
Articles in this issue
over 21 years ago
Split Peaks — A Case Studyover 21 years ago
CDS and LIMS Integrationover 21 years ago
Visual Presentation of Data by Means of Box PlotsAdvertisement
Related to this article
Leon Niezen and Gert Desmet discuss uncertainty-driven LC method development, peak overlap, and moving from in silico to real data.
Leon Niezen and Gert Desmet describe how predictive uncertainty can make automated LC method development more reliable.
Liquid chromatography–mass spectrometry (LC–MS) serum profiling ties lysine compounds to lupus kidney disease.
Liquid chromatography-mass spectrometry (LC–MS) growth lifts Waters Q3; MOBILion ion mobility buy expands proteomics.
Liquid chromatography–tandem mass spectrometry (LC–MS/MS) measures galactose-1-phosphate in dried blood spots to monitor galactosemia.
Sam Whitmarsh explores how retention-time models handle interlaboratory data, novel chemotypes, unusual phases and ionisable compounds, and what labs need to do to build useful in-house models.
Advertisement
Advertisement
Trending on LCGC International
1
AI/ML Now: Toxicity Prediction for Unknown LC–HRMS Features Using Machine Learning
2
LCGC Blog: Building a Career Series That Goes Beyond the Surface
3
From 9000 Clues to a Clinical Test: Mass Spectrometry-Driven Lipidomics for Early Cancer Detection
4
Industry Roundup: Waters Posts Strong Third Quarter as LC–MS and Chromatography Consumables Drive Growth, Acquires Ion Mobility Pioneer MOBILion
5